Breaking
IEEE Spectrum IEEE Smart Village Is Helping to Electrify Rural Cameroon Space.com Should Saturn's huge moon Titan be humanity's next destination, after the moon and Mars? The Guardian Flaws in Kenya’s AI-driven health reforms driving up costs for the poorest Entrepreneur Magazine How to Build Loyalty in a Job-Hopping Economy TechCrunch India’s first space tech unicorn emerges as Skyroot gears up for orbital launch
Breaking
IEEE Spectrum IEEE Smart Village Is Helping to Electrify Rural Cameroon Space.com Should Saturn's huge moon Titan be humanity's next destination, after the moon and Mars? The Guardian Flaws in Kenya’s AI-driven health reforms driving up costs for the poorest Entrepreneur Magazine How to Build Loyalty in a Job-Hopping Economy TechCrunch India’s first space tech unicorn emerges as Skyroot gears up for orbital launch
Nature Biotechnology

Newcomer anti-IL-33 makes strides in COPD

Charlotte Harrison 2026-05-07 · Science
myndfocal
Nature Biotechnology, Published online: 07 May 2026; doi:10.1038/s41587-026-03136-x AstraZeneca’s IL-33 antibody tozorakimab targets two distinct signaling pathways engaged in COPD: inflammation and epithelial dysfunction.

Nature Biotechnology, Published online: 07 May 2026;

doi:10.1038/s41587-026-03136-x

AstraZeneca’s IL-33 antibody tozorakimab targets two distinct signaling pathways engaged in COPD: inflammation and epithelial dysfunction.

— Source: Nature Biotechnology (https://www.nature.com/articles/s41587-026-03136-x)

Science
Read original on Nature Biotechnology →